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Abstract
Radiotherapy (RT) is a potent anti-tumor modality. However, unwanted effects including
increased recurrence and metastasis that involve factors such as cytokines, which induce
complex molecular mechanisms, have also been reported. In a previous study, we showed
that interleukin (IL)-12 and radiotherapy combination treatment suppressed tumor growth
and metastasis in a hepatoma mouse model. In this study, we investigated the mechanism
underlying the IL-12 anti-tumor effect during radiotherapy. In tumor-bearing mice, irradiation
decreased IL-12 expression in the tumors and spleens. However, a number of dendritic
cells infiltrated into the tumors in which IL-12 expression did not decrease. To further study
the underlying detailed mechanism for this decrease in IL-12, LPS-stimulated bone mar-
row–derived dendritic cells (BMDCs) were irradiated, and then IL-12– and IL-6–associated
molecules were examined in irradiated tumors and BMDCs. Irradiation resulted in IL-12
suppression and IL-6 increase. IL-6 and signal transducer and activator of transcription 3
(STAT3) inhibitors restored the irradiation-induced IL-12 decrease via suppression of C-Rel
activation. Taken together, our study suggests that irradiation-induced IL-6 can decrease
IL-12 production through the inhibition of C-Rel phosphorylation by the IL-6/STAT3 signal-
ing pathway.
Introduction
Radiation (RT) is a potent anti-tumor modality used to treat various cancers, including glioma,
breast, colon, lung, liver, head, and neck cancers. Radiation can bring about immune cell
recruitment to tumors through the high-mobility group protein B1 (HMGB1) released by
dying cells, calreticulin caused by cellular stress response, and releases of mediators such as
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inflammatory cytokines and chemokines [1–3]. In particular, RT strongly stimulates interleu-
kin (IL)-6 production by various cells, including immune cells, epithelial cells, and fibroblasts
in radiotherapy [4, 5]. IL-6 is closely involved in growth and metastasis regulation in cancers as
well as in the host immune defense mechanism for foreign pathogens [6, 7]. Classically, IL-6
activates cells through binding to the membrane-bound IL-6 receptor (IL-6R) followed by
homodimerization of a 130 kDa signal-transducing element (gp130) molecules, which facili-
tates the activation of downstream signal cascades [8]. Even in the absence of IL-6R, gp130
expressing cells can be activated by the complex of IL-6 and soluble IL-6R and this process has
been called trans-signaling [9]. The sIL-6R binds to IL-6 with similar affinity as the membrane
bound IL-6R does. A soluble form of the IL-6R (sIL-6R) can be generated by limited proteolysis
of the membrane bound receptor [10, 11] and by translation of a differentially spliced mRNA
[12, 13]. IL-6 directly activates the signal transducers and activators of transcription (STAT)
factors, including STAT1 and STAT3, via the Janus kinases (JAK) [14]. In cancers, the main
mechanisms involved in STAT3 activation are IL-6 autocrine synthesis and IL-6 paracrine acti-
vation from the stroma and infiltrating inflammatory-associated immune cells [15]. Particu-
larly, STAT3 expression in the tumor microenvironment can modulate IL-12 and IL-23
secretion by immune cells such as dendritic cells (DCs) and macrophages [16].
IL-12 is the most critical factor in the Th1 immune response that is induced by foreign path-
ogen–stimulated DCs [17]. IL-12 is considered to be a useful candidate for anti-tumor thera-
pies, as its expression at the tumor site could attract activated lymphocytes such as CD8+ T
cells [18]. In addition, IL-12 is crucial for the development of the peritumoral stroma required
for the acceptance of tumor-migrating T cells [19]. It has also been reported that IL-12p70–
producing DC vaccine elicits CD8+ cytotoxic T cell–mediated immunity [18].
We previously reported the anti-tumor effect of RT combination treatment and IL-12 expressed
through both mesenchymal stem cells and armed oncolytic adenovirus in a murine hepatic cancer
model [20, 21]. However, the detailed molecular mechanism of the IL-12 regulation of RT was not
demonstrated. Therefore, the present study was designed to demonstrate the underlying mecha-
nism of the IL-12/RT combination treatment and IL-12 regulation in DCs by radiation.
Materials and Methods
Reagents
Antibodies against STAT3, phosphorylated STAT3 (p-STAT3), C-Rel, and p-C-Rel were pur-
chased from Bioss (Woburn, MA). WST-1 cell proliferation assay kit was obtained from Roche
Diagnostics (Mannheim, Germany). FITC Anti-mouse B7-1 (Clone 16-10A1), PE Anti-mouse
B7-2 (Clone GL1), PE Anti-Mouse IL-12 p40/p70 (Clone C15.6) and APC Anti-mouse CD11c
(Clone HL3) antibodies were purchased from BD Pharmingen (San Diego, CA). IL-6 and IL-
12 ELISA kit were obtained from R&D System Inc. (Minneapolis, MN). Anti-IL-6 (ab6672)
and anti-CD11c (ab33484) antibodies for immunofluorescent (IF) staining were purchased
from abcam (San Francisco, CA). Anti-IL-12 (NB600-1443) antibody for IF staining was pur-
chased from Novusbio (Littleton, CO). Mouse sIL-6R alpha Simple Step ELISA Kit (ab203360)
was obtained from abcam (Cambridge, MA). Cell Fixation/Permeabilization Kits (BD554715)
for intracellular cytokine analysis was purchased from BD Bioscience (San Jose, CA). Purified
Rat Anti-mouse IL-6 antibody (clone MP5-20F3) was obtained from BD Biosciences. STAT3
inhibitor VI, S31-201 was purchased from Santa Cruz Biotechnology.
Ethics statement
This study was carried out in strict accordance with the recommendations in the Laboratory
Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals of the National
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Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal
Experiments of the Yonsei University Health System (Permit Number: 2012–0177). All animal
surgery was performed after euthanasia using CO2, and all efforts were made to minimize
suffering.
Animal experimental design and X-ray irradiation
Five male C3H/HeN mice, 6–7 weeks old (Central Lab, Japan), were used for each experimental
group. HCa-1 [22, 23] and MIH-2 [24, 25] murine hepatoma cells (1 × 106 cells) in 100 μL PBS
were injected intramuscularly into the right thighs of the mice, and tumors were irradiated
with 10 Gy when tumors reached 8 mm in diameter in a single fraction using an X-Rad 320
irradiator (Precision X-ray, North Branford, CT, USA). Mice were placed at 69 cm from the
radiation source (SSD) for the treatment at a dose rate of 150 cGy/min with 300 kVp X-rays,
using 12.5 mA and a X-ray beam filter consisting of 2.0 mm Al. At 1, 3 and 7 day after 10 Gy
radiation, tumors were collected to evaluate expression of IL-6, IL-12 and DCs. All procedure
of animal research was provided in accordance with the Laboratory Animals Welfare Act, the
Guide for the Care and Use of Laboratory Animals and the Guidelines and Policies for Rodent
experiment provided by the Animal Care and Use Committee of Yonsei University Health Sys-
tem. At the end of the experiment, the experimental mice were euthanized using carbon diox-
ide (CO2) before the tumor reached the maximum allowable size.
DC purification from bone marrow cultures
Bone marrow–derived DCs (BMDCs) were generated from a culture of bone marrow cells from
mouse tibial and femoral bones, as described previously [26, 27]. The cells (1 × 106 cells/mL)
were seeded onto a six-well culture plate in complete Roswell Park Memorial Institute medium
(RPMI)-1640 supplemented with recombinant murine granulocyte macrophage colony-stimu-
lating factor (GM-CSF; 10 ng/mL) and IL-4 (10 ng/mL). The culture medium was changed every
2 days to remove granulocytes. Loosely adherent clustering cells were used as immature DCs for
this study.
Purified BMDCs irradiation
BMDCs were further seeded at 1 × 106/mL/well onto 24-well plates in the presence of 100 ng/mL
lipopolysaccharide (LPS) and then irradiated with 5 or 10 Gy. Supernatants were collected from
each well 24 and 72 h after the irradiation for cytokine measurement.
Cell viability assay
BMDCs were seeded in 96 well flat bottom plates. 24 hours after seeding, cells were irradiated
with 10 Gy. After 72 days, a WST-1 assay was performed as recommended by the manufacturer
(Roche Diagnostics, Mannheim, Germany). Then, the conversion of WST-1 was quantified in
an enzyme-linked immunosorbent assay (ELISA)-reader at 450 nm.
B7-1 and B7-2 expression in DCs
LPS-stimulated BMDCs were irradiated with 5 or 10 Gy and incubated for 48 h. These cells
were resuspended in phosphate-buffered saline (PBS) and stained with FITC-labeled B7-1 and
PE-labeled B7-2 antibodies at a final concentration of 1 μg/mL for 15 min at 4°C. Cells were
then washed twice and immediately analyzed using a FACS Verse flow cytometer (BD Biosci-
ence, San Joes, CA).
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Intracellular staining for IL-12 detection
Surface staining for DCs detection used antibodies to APC-labeled CD11c (BD Bioscience) Fol-
lowing surface staining, intracellular IL-12 was stained as recommended by the manufacturer
using Cell Fixation/Permeabilization Kits (BD Bioscience). Briefly, surface stained BMDCs
were fixed and permeabilized for 40 min in fixation/ permeabilization buffer. After washing
with 1xPerm/Wash buffer, those were stained with PE-conjugated IL-12 antibody for 30 min
on ice/ light protected. Cells were then washed twice with 1xPerm/Wash buffer and immedi-
ately analyzed using a FACS Verse flow cytometer. Samples were analyzed with a FlowJo (Tree
Star Inc, San Carlo, CA)
Immunofluorescence
Differential immunofluorescence analyses were performed on 5-μm cryostat sections. The fol-
lowing antibodies were used: Gout anti-IL-12 (1:100 dilution; Novusbio, NB600-1443), Ham-
ster anti-CD11c (1:100 dilution: Abcam, ab33484), rabbit anti-IL-6 (1:100 dilution; Abcam,
ab6672), and Alexa 488 anti-goat IgG, Alexa 488 anti-Hamster IgG and Alexa 594 anti-rabbit
IgG (Life Technologies). The slides were mounted in SlowFade Gold Antifade Reagent with 40,
6-diamidino-2-phenylindole (Life Technologies).
Cytokine production quantitation
DCs were resuspended in media containing GM-CSF and IL-4 and incubated for the indicated
times in the presence of 100 ng/mL LPS. At the end of the incubation, supernatants were
decanted, non-adherent cells were removed by centrifugation, and the cell-free supernatants
were stored at −70°C until use. IL-6 and IL-12 were measured using commercially-available
enzyme-linked immunosorbent assays (ELISA Quantikine kits, R&D System Inc.) following
the manufacturer’s instructions.
Quantitative real-time PCR analysis
Total RNA was extracted from DCs using TRIzol (Invitrogen), and cDNA was synthesized
from 1μg of total RNA by reverse transcription (Qiagen). Real-time PCR analysis was per-
formed using a Step One Plus-Real Time system (Applied Biosytems, Tokyo, Japan) to measure
SYBR Green (Applied Biosystems). Relative amounts of mRNA were normalized to GAPDH
mRNA levels within each sample. The primer sequences used were: IL-12p40: Forward 5’-AA
C CAT CTC CTG GTT TGC CA-3’ and Reverse 5’-CGG GAG TCC AGT CCA CCT C-3’,
IL-12p35: Forward 5’- CCC TTG CAT CTG GCG TCT ACA CTG CTG C -3’ and Reverse
5’—AGG AGG GCA AGG GTG GCC AAA AAG AGG A-3’.
Statistical analysis
The data are presented as means ± SD, and statistical significance between groups was assessed
by unpaired two-sided t-tests. All experiments were performed at least three times. Differences
of P< 0.05 () and P< 0.01 () were considered to be statistically significant.
Results
Irradiation inhibited IL-12 production by DCs
To determine whether irradiation regulates IL-12 expression in tumors, HCa-1 and MIH-2
cells (1 × 106 cells) were injected into the right thighs of C3H/HeN mice, and tumors were irra-
diated with 10 Gy when the tumor volume reached about 250 mm3. HCa-1 is a rapidly-growing
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hepatoma that is resistant to radiation, while MIH-2 is a slow-growing hepatoma that is sensi-
tive to radiation in relative comparison to HCa-1. IL-12 is mainly produced by DCs in response
to tumor-associated antigens or during the release of damage-associated molecular patterns
(DAMPs) such as HMGB1, HSP, and calreticulin in the tumor microenvironment [3]. There-
fore, tumors were co-stained with IL-12 and CD11c antibodies to investigate the presence of
DCs and IL-12 release from DCs at 1, 3, and 7 days after irradiation in tumors. As shown in Fig
1A and 1B, irradiation dramatically decreased IL-12 expression over time after irradiation,
while the levels of DCs as CD11c-positive cells were not significantly changed by irradiation in
both tumors. In addition, IL-12 secretion from the spleens of the irradiating tumor group was
decreased compared to the control tumor group (Fig 1C). The tumor associated-soluble factors
such as HMGB1, growth factors, chemokines and cytokines could contribute to the tumor
growth through the regulation and alteration of tumor microenvironment. Therefore, to inves-
tigate possible tumor-derived soluble factors induced by irradiation that contributed to the
decrease of IL-12 in DCs, DCs were isolated from mouse bone marrow cells (BMDCs) that
were differentiated in media containing IL-4 (10 ng/mL) and GM-CSF (10 ng/mL) for 6 days
and then, these were incubated for 72 h in supernatants of MIH-2 cell irradiated with or with-
out 10 Gy. BMDCs were analyzed by flow cytometry (FACS) after intracellular staining for IL-
12 detection. As a result, BMDCs of 10 Gy irradiated-MIH-2 culture supernatant showed
lower IL-12 level than BMDCs of non-irradiated MIH-2 culture supernatant (Fig 1D). There-
fore, to investigate whether irradiation regulates IL-12 production by DCs, BMDCs were cul-
tured for 24 and 72 h after irradiation in media containing GM-CSF and IL-4 with the
presence of 100 ng/mL LPS, which was used to allow DCs to mature. IL-12 was measured in
the culture supernatant. The resulting IL-12 secretion increased slightly after 24 h of irradia-
tion; however, it decreased significantly after 72 h of irradiation (Fig 1E). DC viability was not
affected by irradiation (Fig 1F). Also, to measure the activation of DCs, the expression of B7.1
as a co-stimulating molecule was assessed by FACS. BMDCs were subcultured in GM-CSF–
and IL-4–supplemented media for 48 h in 24-well plates after irradiation in the presence of
LPS. As shown in Fig 1G, irradiation led to a decrease in B7.1 expression when compared to
LPS treatment alone. These results suggest that irradiation could suppress IL-12 expression in
tumors and tumor microenvironments, including DCs.
Irradiation-induced IL-6 suppressed IL-12 production in tumors and DCs
Hoentjen et al. showed that IL-10 induced–STAT3 regulates IL-12 production in LPS-stimu-
lated DCs [28]. STAT3 is activated in response to IL-6 [29], and irradiation can substantially
induce IL-6 production. Therefore, we investigated whether irradiation-induced IL-6 could
regulate IL-12 production in tumors. As shown in Fig 2A and 2B, IL-6 expression was upregu-
lated in both types of 10 Gy irradiated–tumors compared to the control tumors, whereas IL-12
expression decreased as opposed to IL-6 expression. In addition, 10 Gy irradiated BMDCs
exhibited higher expression of IL-6R and sIL-6R (Fig 2C and 2D) than no-irradiation. Addi-
tionally, IL-6 treatment to BMDCs decreased IL-12 secretion from BMDCs compared to no
treatment (Fig 2E). We also investigated whether irradiation regulated IL-6 production in DCs.
BMDCs were incubated in media containing GM-CSF, IL-4, and LPS for 24 and 72 h after 10
Gy irradiation. As a result, IL-6 secretion in the culture supernatant from DCs was highly
increased by irradiation at both 24 and 72 h (Fig 2F). Considering that IL-6 secreted by irradia-
tion from DCs and tumor cells may affect DCs through autocrine and paracrine signaling, we
investigated whether IL-6 could hinder IL-12 production in DCs. LPS-stimulated BMDCs were
immediately treated with or without an anti-IL-6 antibody after irradiation. As a result, IL-6
inhibition rescued IL-12 production from the irradiation-induced inhibition (Fig 2G).
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Additionally, irradiation suppressed the expression of B7-1 and B7-2 in a radiation dose depen-
dent manner compared to LPS treatment alone, and anti-IL-6–antibody treatment rescued B7-
1 and B7-2 expression from the irradiation-induced inhibition (Fig 2H). Therefore, these
results indicate that irradiation-induced IL-6 could suppress IL-12 production by DCs.
Irradiation-induced STAT3 activation inhibited IL-12 secretion from DCs
STAT3 was originally identified as an acute-phase response factor that responds to stimulation
by IL-6 [30]. As STAT3 can also be activated by radiation via regulation of other molecules
such as survivin as well as IL-6 induction [31], STAT3 inhibitor was used to test whether the
STAT3 activation was involved in the irradiation-induced decrease in IL-12. S31-201, STAT3
inhibitor, was added to LPS-stimulated BMDCs receiving 10 Gy radiation, and were incubated
for the indicated times. As shown in Fig 3A and 3B, S31-201 inhibited phosphorylation of
stat3, but it doesn’t significantly affect cell viability. STAT3 inhibitor treatment restored the
expression of IL-12 and B7-1 that had been inhibited by radiation (Fig 3C and 3D). Anti-IL-6
antibody treatment inhibited STAT3 phosphorylation in LPS-stimulated BMDCs receiving 10
Gy irradiation (Fig 3E). These results suggest that irradiation induced IL-6 secretion, which
activated STAT3, and finally could inhibit IL-12 production in DCs.
IL6-induced STAT3 activation interfered with IL-12 synthesis through
suppression of C-Rel phosphorylation in irradiated-DCs
To determine the underlying mechanism by which IL-6 inhibited IL-12 production in DCs, we
examined the levels of IL-12 mRNA in LPS-stimulated DCs with or without irradiation. As
shown in Fig 4A and 4B, inhibition of IL-6 increased the levels of IL-12p40 as well as IL-12p35
mRNA. According to a previous report, NF-kappa B (NF-kB) family members, including p50/
p65 and p50/C-Rel, act as transcriptional factors in IL-12p40 activation [32]. In particular,
STAT3 can affect IL-12 production via C-Rel [28]. Therefore, we investigated the expression of
C-Rel in LPS-stimulated DCs. LPS-stimulated BMDCs were incubated with or without irradia-
tion for 16 h and collected for western blotting. C-Rel expression was increased by the anti-IL-
6 antibody and STAT3 inhibitor in 10 Gy-irradiated BMDCs (Fig 4C and 4D). Thus, as shown
in Fig 5, irradiation could interfere with IL-12 synthesis via inhibition of C-Rel activation
through the IL-6/STAT 3 pathway in DCs.
Discussion
We previously showed the anti-tumor effect of an IL-12/RT combination treatment [20, 21].
However, its detailed molecular mechanism had not been demonstrated. Therefore, the present
study was designed to define the role of IL-12 in radiotherapy and its underlying mechanism.
We showed that irradiation inhibited IL-12 expression in HCa-1 and MIH-2 tumors and
spleens of tumor-bearing mice. However, the number of DCs that mainly secrete IL-12 was
more an increase than a decrease in both types of irradiated tumors (HCa-1 and MIH-2) com-
pared to the control tumors. The HCa-1 and MIH-2 tumor cells that were used in this study
Fig 1. Irradiation inhibited IL-12 expression in tumors of hepatoma-bearingmice in vivo and DCs in vitro. HCa-1 and MIH-2 cells were injected
intramuscularly into the right thighs of the mice, and tumors were irradiated with 10 Gy of radiation. Shown are IL-12 and DC (CD11c+) expressions at 1, 3,
and 7 days after irradiation in (a) HCa-1 and (b) MIH-2 tumors and (c) IL-12 expression in the spleens of HCa-1 bearing mice (** P < 0.01). (d) IL-12
expression in BMDCs incubated with supernatant of MIH-2 tumor cells or supernatant of 10 Gy irradiating MIH-2 tumor cells. (** P < 0.01). DCs were
differentiated from bone marrow of C3H/HeN normal mice (BMDCs). These were incubated for 72 h in supernatant of MIH-2 tumor cells with or without 10 Gy
irradiation. IL-12 was intracellular stained with IL-12 antibody and analyzed by FACS. BMDCs also were stimulated with LPS (100 ng/mL) to allow maturation
and irradiated with 10 Gy of radiation. (e) IL-12 expression (** P < 0.01), (f) cell viability, and (g) B7.1 expression in LPS stimulated BMDCs receiving 10 Gy
radiation. (* P < 0.05). Data are from three independent experiments with five mice per group.
doi:10.1371/journal.pone.0146463.g001
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differ in their sensitivity to radiation and potential for tumorigenesis [33]. Therefore, these
results suggest that the observed immune responses, including cytokine regulation and
immune cell infiltration by radiation, may have occurred regardless of the radio-sensitivity of
the tumors. Many previous studies suggest that radiotherapy can lead to immunogenic cell
death via recruitment of immune cells such as DCs, macrophages, and lymphocytes into the
tumors by the release of radiation-induced DAMPs including HMGB1, HSP, and calreticulin
[34, 35]. Indeed, the induction of HMGB1 in tumors was caused by 10-Gy irradiation (data not
shown), which might have triggered maturation and infiltration of DCs via Toll like receptor 4
(TLR4) in this study. In spite of an increase in DCs recruitment, IL-12 expression was dimin-
ished in irradiated tumors. It has been reported that although DCs are resistant to radiation-
induced apoptosis, radiation inhibits IL-12 secretion from mature DCs as a consequence of
immune response suppression via impairing the priming ability of T cells [36]. However, the
underlying mechanism by which radiation can downregulate IL-12 remains unclear. Accord-
ingly, we investigated the molecular mechanism involved in the suppression of IL-12 expres-
sion by irradiation in DCs. In current study, irradiation slightly induced IL-12 expression in
BMDCs 24 h after irradiation. In contrast, at 72 h after irradiation, the irradiation significantly
suppressed IL-12 secretion by LPS-treated BMDCs, as well as B7.1 and B7.2 expression. These
results indicate that IL-12 production could be affected by radiation-stimulated molecular fac-
tors in later responses. Accordingly, to identify the mechanism regulating IL-12 in irradiated-
BMDCs, we investigated IL-6/STAT3 signaling, as STAT3 activation can disrupt IL-12 produc-
tion and STAT3 is a downstream signaling molecule of the IL-6 receptor [37]. It has been
reported that STAT3 signaling regulates the IL-12/IL-23 balance, which directs the transcrip-
tional activation of the IL-23/p19 gene and inhibits IL-12/p35 gene expression in tumor-associ-
ated DCs [16]. Moreover, Radiation strongly enhances IL-6, which inhibits radiation-induced
apoptosis [4]. Radiation also can induce cellular senescence, which can increase IL-6 release
[38]. Indeed, 10 Gy irradiation elevated expression of β-galactosidase; senescence marker in
tumors (data not shown). Accordingly, RT-induced cellular senescence might contribute to
secretion of IL-6 in this study. IL-6 signal cascade is triggered by IL-6/IL-6R complex via mem-
brane-bound receptor and a soluble form of the IL-6R, which is frequently associated with
inflammatory diseases and increased risk of cancers [15]. Cellular activation by IL-6 requires
binding to IL-6 receptor and resulting recruitment of two gp130. This initiates phosphorylation
of gp130-associated Janus kinases (JAKs), which stimulates their phosphorylation via binding
of STAT1/STAT3 to gp130 [39]. In the present study, 10 Gy irradiation enhanced expression
of cell membrane bounded IL-6R and soluble IL-6R as well as IL-6 production, which might
suppress IL-12 synthesis in BMDCs. Interestingly, treatment with an anti-IL-6 antibody and a
STAT3 inhibitor rescued IL-12 expression in irradiated-BMDCs. These results suggest that the
IL-6/STAT3 signaling pathway is closely related to the downregulation of IL-12 by radiation in
irradiated BMDCs. Radiation could also activate both IL-6 signaling pathways of the classic sig-
naling via membrane binding receptor and trans-signaling via soluble receptor. Given that NF-
kBp50/C-Rel transcription factor can regulate IL-12/p40 gene expression [32], we further
investigated NF-kB signaling to better understand the molecular mechanism involved in IL-12
Fig 2. Irradiation-induced IL-6 suppressed IL-12 expression in tumors of hepatoma-bearingmice in vivo and DCs in vitro. IL-6 and IL-12 were
measured at 1, 3, and 7 days after 10 Gy irradiation of tumors. Shown are the expressions of IL-6 and IL-12 in (a) HCa-1 and (b) MIH-2 tumors (* P < 0.05).
BMDCs were prepared from bone marrow of mice and stimulated with LPS. (c) IL-6 expression analyzed at the indicated times by ELISA in irradiated or non-
irradiated BMDCs in vitro. (d) IL-6R (** P < 0.01, vs No IR) and (e) sIL6R (** P < 0.01) were evaluated at 2 day after 10 Gy irradiation to BMDCs by FACS
and ELISA, respectively. BMDCs were treated without or with IL-6 (20 ng/mL) plus LPS. (f) Down regulation of IL-12 production by IL-6 treatment in BMDCs
(** P < 0.01). BMDCs were stimulated with LPS for activation and cultured with or without anti-IL-6 antibody (final concentration of 500 ng/mL) during the
indicated times after irradiation in vitro. IL-6 and IL-12 were analyzed by ELISA. (g) Recovery of IL-12 production and (h) B7-1/ B7-2 expression using an anti-
IL-6 antibody in irradiated-BMDCs stimulated with LPS in vitro. (** P < 0.01, * P < 0.05). Data are from three independent experiments.
doi:10.1371/journal.pone.0146463.g002
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suppression by the IL-6/STAT3 signaling in DCs. In addition, Hoentjen et al. showed that
upregulation of the IL-12/p40 gene in IL-10 deficient mice is due to enhanced C-Rel recruit-
ment to the IL-12p40 promoter in the absence of activated STAT3 [28]. Thus, activated-
STAT3 inhibits IL-12 production through the interruption of C-Rel recruitment to the IL-
12p40 promoter. IL-12 plays a crucial role in regulating both innate and adaptive immune
responses and can be a potent anti-tumor agent that can be used in combination with other
cytokines with anti-tumor activities [40]. In our study, irradiation strongly stimulated the
phosphorylation of STAT3, which inhibited C-Rel phosphorylation in LPS-stimulated
BMDCs. Additionally, irradiation-induced inhibition of C-Rel phosphorylation was rescued by
anti-IL-6 antibody and STAT3 inhibitor. Thus, as shown in Fig 5, irradiation-induced inhibi-
tion of C-Rel phosphorylation involved the IL-6/STAT3 signaling pathway in maturated DCs,
which resulted in the suppression of IL-12 synthesis.
In conclusion, the present study is the first to report that RT inhibits IL-12 through the IL-
6/STAT3 signaling pathway in tumors and tumor-associated DCs. Our results imply that IL-12
treatment may be a useful therapeutic modality for cancer patients receiving RT.
Fig 3. STAT3 activation suppressed IL-12 expression in irradiated-BMDCs. LPS-stimulated BMDCs were pretreated with S31-201, STAT3 inhibitor
(final concentration of 50 μM) for 24 h prior to 10 Gy irradiation, and then p-STAT3 and STAT3 were analyzed by western blotting at 1 h after irradiation. (a)
STAT3 expression and (b) cell viability in S31-201 treated BMDCs. LPS-stimulated BMDCs were treated with or without S31-201 followed by 10 Gy
irradiation. The expression of IL-12 and B7-1 were evaluated at 3 day after irradiation by FACS. (c) Recovery of IL-12 and (d) B7-1 expression by S31-201 in
LPS-stimulated BMDCs receiving 10 Gy radiation (** P < 0.01). (e) Expression of p-STAT3 suppressed by anti-IL-6 antibody treatment in LPS-stimulated
BMDCs receiving 10 Gy radiation. Data are from three independent experiments.
doi:10.1371/journal.pone.0146463.g003
Fig 4. IL-6/STAT3 signaling interfered with IL-12 synthesis via the blocking of C-Rel phosphorylation in irradiated BMDCs. BMDCs were stimulated
with LPS for maturation and cultured with anti-IL-6 antibody (500 ng/mL) or STAT3 inhibitor (50 μM) for 16 h after irradiation. The IL-12 mRNA level was
evaluated using quantitative real-time PCR. (a) Upregulation of IL-12p40 mRNA and (b) IL-12p35 mRNA by anti-IL-6 antibody in LPS-stimulated BMDCs
receiving 10 Gy radiation (* P < 0.05). (c) Recovery of radiation-suppressed C-Rel phosphorylation by IL-6 blocking and (d) STAT3 inhibition in LPS-
stimulated BMDCs receiving 10 Gy radiation. Data are from three independent experiments.
doi:10.1371/journal.pone.0146463.g004
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